UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026175
Receipt number R000030077
Scientific Title Comparison of concentration of 5-ASA and acetyl 5-ASA in mucosa in time-dependent mesalazine granule preparation and pH-dependent mesalazine tablet for patients with ulcerative colitis
Date of disclosure of the study information 2017/03/01
Last modified on 2019/03/12 13:37:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison of concentration of 5-ASA and acetyl 5-ASA in mucosa in time-dependent mesalazine granule preparation and pH-dependent mesalazine tablet for patients with ulcerative colitis

Acronym

Comparison of concentration of 5-ASA and acetyl 5-ASA in mucosa in time-dependent mesalazine granule preparation and pH-dependent mesalazine tablet for patients with ulcerative colitis

Scientific Title

Comparison of concentration of 5-ASA and acetyl 5-ASA in mucosa in time-dependent mesalazine granule preparation and pH-dependent mesalazine tablet for patients with ulcerative colitis

Scientific Title:Acronym

Comparison of concentration of 5-ASA and acetyl 5-ASA in mucosa in time-dependent mesalazine granule preparation and pH-dependent mesalazine tablet for patients with ulcerative colitis

Region

Japan


Condition

Condition

Ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In this study, patients with ulcerative colitis in a fixed amount of time-dependent mesalazine granule preparation or orally administered pH-dependent mesalazine tablets underwent rectal examination by clinical findings, specimen examination, image examination, and lower endoscopic examination of periodic examination , Secondary utilization of biopsy tissue in the cecum to measure the concentration of 5-ASA and acetyl 5-ASA in the colonic mucosa and to compare the usefulness of time-dependent mesalazine granule preparation and pH dependent mesalazine tablet.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Changes in the concentrations of 5-ASA and acetyl 5-ASA in rectal, cecal biopsy tissue, remission induction rate / maintenance rate (Mayo 1 or less)

Key secondary outcomes

Drug efficacy rate (improvement of CAI by 30% or more), remission maintenance rate and duration, side effect occurrence rate, endoscopic findings, CRP, change amount of calprotectin in the stool


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Diagnosis

Type of intervention

Device,equipment

Interventions/Control_1

Time dependent mesalazine granule formulation After bottom of the 8th week from the start of administration, the lower endoscopy was performed and the mucous membrane was collected from the cecum and rectum by biopsy and the concentration of 5-ASA and acetyl 5-ASA in the mucosa was measured in the mucosa .

Interventions/Control_2

PH dependent mesalazine granule preparation Lower endoscopy was performed 8 weeks after the start of administration, mucosa was collected from the cecum and rectum by biopsy, and the concentration of 5-ASA and acetyl 5-ASA in the mucosa was measured at the drug part .

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

99 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Patients with remission, mild or moderate ulcerative colitis (endoscopic Mayo score 2 or less, or less severe classification by Suzuki team of the Ministry of Health, Labor and Welfare)
2) Patients who aged 20 years or older at the time of acquiring consent.
3) Patients who have not changed the contents of medication to the original disease within the last 8 weeks of participation in this study.
4) Time-dependent mesalazine granule preparation 2.0 - 4.0 mg / day or pH dependent mesalazine tablet 2.4 - 4.8 mg / day Patients who received written informed consent.

Key exclusion criteria

1) People with severe or fulminant ulcerative colitis. (Mayo score 2 or less, or less severe classification by Suzuki team of Ministry of Health, Labor and Welfare)
2) Patients undergoing total colon resection, subtotal puncture surgery etc.
3) Patients with liver dysfunction and renal dysfunction.
4) Patients undergoing antithrombotic therapy or anticoagulant therapy and patients with thrombocytopenia.
5) Pregnant women or patients who may be pregnant, breast-feeding patients.
6) Patients who are merging psychosis or psychiatric symptoms and are considered difficult to participate in the study.
7) Other patients who decided that the doctor in charge is inappropriate, such as a decline in compliance.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tnakanari Kitazono

Organization

Kyushu University

Division name

Department of Medicine and Clinical Science, Graduate School of Medical Sciences

Zip code


Address

Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan

TEL

092-642-5261

Email

akharada@intmed2.med.kyushu-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akira Harada

Organization

Kyushu University

Division name

Department of Medicine and Clinical Science, Graduate School of Medical Sciences

Zip code


Address

Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan

TEL

092-642-5261

Homepage URL

http://www.gut.med.kyushu-u.ac.jp/

Email

akharada@intmed2.med.kyushu-u.ac.jp


Sponsor or person

Institute

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University

Institute

Department

Personal name



Funding Source

Organization

Kyushu University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

九州大学病院(福岡県)


Other administrative information

Date of disclosure of the study information

2017 Year 03 Month 01 Day


Related information

URL releasing protocol

http://www.gut.med.kyushu-u.ac.jp/

Publication of results

Unpublished


Result

URL related to results and publications

http://www.gut.med.kyushu-u.ac.jp/

Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2017 Year 02 Month 17 Day

Date of IRB

2017 Year 02 Month 17 Day

Anticipated trial start date

2017 Year 06 Month 23 Day

Last follow-up date

2019 Year 03 Month 08 Day

Date of closure to data entry

2019 Year 03 Month 08 Day

Date trial data considered complete

2019 Year 03 Month 31 Day

Date analysis concluded

2019 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2017 Year 02 Month 16 Day

Last modified on

2019 Year 03 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030077


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name